Related Experiment Video
Updated: Mar 10, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Erythrodermic Psoriasis Treated with Apremilast
John Arcilla1, Daniel Joe1, Johnathan Kim1
1Department of Medicine, Loma Linda University School of Medicine.
Dermatology Reports
|December 13, 2016
Summary
Erythrodermic psoriasis, a severe skin condition, can be triggered by steroid withdrawal. This case study shows successful treatment with apremilast and cyclosporine, though apremilast use was limited by side effects.
Area of Science:
- Dermatology
- Immunology
Background:
- Erythroderma is a critical dermatological condition with diffuse erythema and potential multi-organ dysfunction.
- Erythrodermic psoriasis, the most common erythroderma subtype, requires prompt recognition and treatment.
- Current management involves supportive care and anti-inflammatory, immunosuppressive, or biologic agents.
Observation:
- A case of psoriatic erythroderma triggered by systemic steroid withdrawal is presented.
- The patient experienced an initial positive response to apremilast and cyclosporine therapy.
Findings:
- Successful treatment of steroid-withdrawal-induced psoriatic erythroderma was achieved with a combination of apremilast and cyclosporine.
- Apremilast use was discontinued due to the development of atrial fibrillation.
Implications:
- This case highlights a potential therapeutic strategy for severe psoriatic erythroderma.
- It also underscores the importance of monitoring for cardiovascular side effects with apremilast.
- Further research may explore optimizing combination therapies for erythrodermic psoriasis.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
570
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
570
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
592
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
592
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688
01:21Rheumatic Heart Disease III: Medical Management
445
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
445
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
676
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
676